Business
Citrine Global Corp.’s (OTCQB: CTGL) Subsidiary, Cannovation Center Israel Ltd., is Pleased to Announce the Launch of its "Green Side by Side" Products Line and the Signing of an Agreement with Intelicanna to Sell the Products in Israel
Citrine Global Corp.’s (OTCQB: CTGL) Subsidiary, Cannovation Center Israel Ltd., is Pleased to Announce the Launch of its "Green Side by Side" Products Line and the Signing of an Agreement with Intelicanna to Sell the Products in Israel.
About this update from Citrine Global Corp.
[{"type":"text","content":"\n Tel Aviv, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Citrine Global Corp.’s (OTCQB: CTGL) subsidiary, Cannovation Center Israel Ltd. (Cannovation), announced that it has launched its \"Green Side by Side\" products line and has entered into a Collaboration Agreement with Intelicanna Ltd. to sell and market the products in Israel as complementary products for medical cannabis patients. The \"Green Side by Side\" products line contains natural & herbal formulas based on researched and science-based plants, herbal extracts, mushrooms, and other natural ingredients. The products are in multiple form factors, including oral sprays, capsules, tablets among others. The Agreement with Intelicanna for sales & marketing of the product line in Israel is part of Cannovation's strategy to expand sales through collaboration with local partners in Europe, North America, Asia and more Intelicanna Ltd. is a public company traded on the Tel Aviv Stock Exchange and is primarily engaged in plant genetics, agro technologies, product development, sales and marketing of medical cannabis products. The \"Green Side by Side\" product line is part of Cannovation's strategy to bring to market plant-based wellness and pharma innovation and products based on research and development. As previously disclosed, in October 2021 a Provisional Patent Application No: 63/257,673 for “PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE-EFFECTS ASSOCIATED WITH THE USE OF CANNABIS, CANNABINOIDS AND RELATED PRODUCTS” was filed. The invention addresses the needs of medical cannabis patients who experience side effects related to their cannabis treatment. Research indicates that there are medical cannabis patients who experience side effects from their medical cannabis treatment such as: dry mouth, bad mouth taste, headaches, dry eyes, dizziness, drowsiness, fatigue, nausea, vomiting, among other symptoms. Some medical cannabis patients continue treatment despite experiencing side effects, while others choose to discontinue treatment even when achieving good clinical results with the cannabis treatment1. While the medical cannabis treatment market is forecast2 to nearly triple from $16 billion in 2021 to $46 billion in 2026, there is a growing and unmet need to address the side effects associated with medical cannabis treatment. Ora Elhar...